The two suits address a total of 17 patents on elements of continuous glucose monitors, or CGMs.
Abbott and Dexcom, Inc. will face off in court over patents on technology used in continuous glucose monitor technology – a major growth area for both companies.
The battle began on 30 June when Dexcom filed suit in Texas federal court claiming that Abbott’s FreeStyle Libre product line violated five of Dexcom’s patents. But the next day,
HHS Secretary Robert F. Kennedy, Jr. is asking the public to help cut waste across the government’s health agencies. Kennedy announced a 60-day comment period allowing the public to take part in a broader federal initiative to reduce regulations and increase transparency.
The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.
With medtech businesses typically managing investment cycles on a three- to five-year basis, local regulatory processes and forward costs of market entry must offer an attractive environment in which companies can plan for growth, says McDermott Will and Emery’s partner and head of healthcare and life sciences, Sharon Lamb. Broad-scale improvements to NICE’s evaluation offerings would similarly enhance the UK’s value to innovators.
